On September 2, 2025, Olema Pharmaceuticals announced a collaboration with Pfizer to evaluate palazestrant with atirmociclib in a clinical trial for breast cancer. This study will assess safety and combinability, with joint ownership of clinical data but Olema retaining marketing rights.